Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 332.91 USD 2.25% Market Closed
Market Cap: 9.3B USD
Have any thoughts about
Bio Rad Laboratories Inc?
Write Note

Bio Rad Laboratories Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bio Rad Laboratories Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Bio Rad Laboratories Inc
NYSE:BIO
Total Equity
$7.5B
CAGR 3-Years
-21%
CAGR 5-Years
8%
CAGR 10-Years
13%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Equity
$49B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Equity
$51.3B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
8%
Mettler-Toledo International Inc
NYSE:MTD
Total Equity
-$154.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Total Equity
$5.9B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
0%
IQVIA Holdings Inc
NYSE:IQV
Total Equity
$7B
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
N/A
No Stocks Found

Bio Rad Laboratories Inc
Glance View

Market Cap
9.3B USD
Industry
Life Sciences Tools & Services

Bio-Rad Laboratories Inc. is a global leader in the life sciences and clinical diagnostics industries, renowned for its innovative technologies that empower researchers and healthcare professionals. Founded in 1952, Bio-Rad has developed a diverse portfolio of products that serve a wide range of applications, from advancing scientific research in genomics and proteomics to enhancing diagnostic capabilities in clinical laboratories. The company operates through two key segments: Life Science and Diagnostics, which together create synergies that drive growth. With a commitment to quality and customer satisfaction, Bio-Rad has built a reputation for reliability and technical excellence, making it a trusted partner in the quest for scientific breakthroughs and improved patient care. Investors looking at Bio-Rad will find a resilient company with strong fundamentals and a consistent track record of performance. The firm benefits from ongoing trends in healthcare and biotechnology, with increasing demand for precision medicine and advanced molecular diagnostics leading to robust revenue streams. Bio-Rad's global footprint and extensive distribution network not only mitigate risks associated with market fluctuations but also position the company to capitalize on emerging technologies and expanding international markets. With a strategic focus on innovation and a history of prudent financial management, Bio-Rad Laboratories offers investors an opportunity to be part of a company that is at the forefront of scientific advancement while also delivering solid returns.

BIO Intrinsic Value
376.25 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Bio Rad Laboratories Inc's Total Equity?
Total Equity
7.5B USD

Based on the financial report for Sep 30, 2024, Bio Rad Laboratories Inc's Total Equity amounts to 7.5B USD.

What is Bio Rad Laboratories Inc's Total Equity growth rate?
Total Equity CAGR 10Y
13%

Over the last year, the Total Equity growth was -11%. The average annual Total Equity growth rates for Bio Rad Laboratories Inc have been -21% over the past three years , 8% over the past five years , and 13% over the past ten years .

Back to Top